Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting
Wakefield, Mass., May, 16th, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 16, 2023
This article is featured on another website.
Go to article
March 10, 2026
Meet HiRO at PHUSE US Connect 2026 in Austin
We’re excited to join PHUSE US Connect 2026, taking place March 22–26, 2026 in Austin,…
March 10, 2026
Meet HiRO at PHUSE US Connect 2026 in Austin
We’re excited to join PHUSE US Connect 2026, taking place March 22–26, 2026 in Austin,…
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…